- Home
- SWK vs EXEL Comparison
SWK vs EXEL Comparison
Compare SWK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWK | EXEL |
|---|---|---|
| Founded | 1843 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SWK | EXEL |
|---|---|---|
| Price | $72.51 | $44.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 24 |
| Target Price | ★ $92.25 | $44.73 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | ★ 2.90 | 2.38 |
| Revenue | ★ $15,166,300,000.00 | $2,288,218,000.00 |
| Revenue This Year | $0.05 | $9.14 |
| Revenue Next Year | $3.01 | $12.51 |
| P/E Ratio | $25.02 | ★ $18.67 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $53.91 | $31.90 |
| 52 Week High | $91.06 | $49.62 |
Technical Indicators
Market Signals| Indicator | SWK | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 63.52 |
| Support Level | $69.27 | $43.00 |
| Resistance Level | $72.20 | $44.79 |
| Average True Range (ATR) | 2.14 | 1.03 |
| MACD | 0.82 | 0.06 |
| Stochastic Oscillator | 91.22 | 83.48 |
Price Performance
Historical ComparisonAbout SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.